AU2011340258C1 - Hydantoin derivatives useful as Kv3 inhibitors - Google Patents

Hydantoin derivatives useful as Kv3 inhibitors Download PDF

Info

Publication number
AU2011340258C1
AU2011340258C1 AU2011340258A AU2011340258A AU2011340258C1 AU 2011340258 C1 AU2011340258 C1 AU 2011340258C1 AU 2011340258 A AU2011340258 A AU 2011340258A AU 2011340258 A AU2011340258 A AU 2011340258A AU 2011340258 C1 AU2011340258 C1 AU 2011340258C1
Authority
AU
Australia
Prior art keywords
oxy
imidazolidinedione
methyl
ethyl
benzofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011340258A
Other languages
English (en)
Other versions
AU2011340258A1 (en
AU2011340258B2 (en
Inventor
Giuseppe Alvaro
Paolo Dambruoso
Anne Decor
Charles Large
Agostino Marasco
Simona Tommasi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autifony Therapeutics Ltd
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1020607.6A external-priority patent/GB201020607D0/en
Priority claimed from PCT/EP2010/068946 external-priority patent/WO2011069951A1/en
Priority claimed from GBGB1109508.0A external-priority patent/GB201109508D0/en
Priority claimed from GBGB1113757.7A external-priority patent/GB201113757D0/en
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Publication of AU2011340258A1 publication Critical patent/AU2011340258A1/en
Application granted granted Critical
Publication of AU2011340258B2 publication Critical patent/AU2011340258B2/en
Publication of AU2011340258C1 publication Critical patent/AU2011340258C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2011340258A 2010-12-06 2011-12-06 Hydantoin derivatives useful as Kv3 inhibitors Active AU2011340258C1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB1020607.6A GB201020607D0 (en) 2010-12-06 2010-12-06 Novel compounds
AUPCT/EP2010/068946 2010-12-06
GB1020607.6 2010-12-06
PCT/EP2010/068946 WO2011069951A1 (en) 2009-12-11 2010-12-06 Imidazolidinedione derivatives
GB1109508.0 2011-06-07
GBGB1109508.0A GB201109508D0 (en) 2011-06-07 2011-06-07 Novel compounds
GBGB1113757.7A GB201113757D0 (en) 2011-08-10 2011-08-10 Novel compounds
GB1113757.7 2011-08-10
PCT/GB2011/052414 WO2012076877A1 (en) 2010-12-06 2011-12-06 Hydantoin derivatives useful as kv3 inhibitors

Publications (3)

Publication Number Publication Date
AU2011340258A1 AU2011340258A1 (en) 2013-05-30
AU2011340258B2 AU2011340258B2 (en) 2016-05-19
AU2011340258C1 true AU2011340258C1 (en) 2016-10-20

Family

ID=45464001

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011340258A Active AU2011340258C1 (en) 2010-12-06 2011-12-06 Hydantoin derivatives useful as Kv3 inhibitors

Country Status (17)

Country Link
US (13) US9346790B2 (https=)
EP (1) EP2649066B1 (https=)
JP (2) JP5913357B2 (https=)
KR (1) KR101862375B1 (https=)
CN (1) CN103328467B (https=)
AU (1) AU2011340258C1 (https=)
BR (1) BR112013013914B1 (https=)
CA (1) CA2817205C (https=)
DK (1) DK2649066T3 (https=)
EA (2) EA023768B1 (https=)
ES (1) ES2560304T3 (https=)
IL (3) IL226256A0 (https=)
MX (1) MX338489B (https=)
PL (1) PL2649066T3 (https=)
SG (2) SG190203A1 (https=)
WO (1) WO2012076877A1 (https=)
ZA (1) ZA201403529B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2509961B1 (en) 2009-12-11 2016-03-09 Autifony Therapeutics Limited Imidazolidinedione derivatives
EA023768B1 (ru) 2010-12-06 2016-07-29 Отифони Терапеутикс Лимитед ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
CN103596943B (zh) * 2011-06-07 2016-10-12 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
EP2788339B1 (en) 2011-12-06 2016-03-09 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
US9669030B2 (en) * 2012-05-22 2017-06-06 Autifony Therapeutics Limited Hydantoin derivatives as Kv3 inhibitors
US9422252B2 (en) 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
WO2013182851A1 (en) * 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
HK1225728B (en) * 2013-12-20 2017-09-15 Gilead Sciences, Inc. Fusion heterocyclic compounds as ion channel modifiers
UA124329C2 (uk) 2014-01-16 2021-09-01 ЕфЕмСі КОРПОРЕЙШН Піримідинілоксибензольні похідні як гербіциди
US10183237B2 (en) * 2014-03-21 2019-01-22 Biotage Ab Method and apparatus for the equilibration of a packed chromatography column
CN103980205B (zh) * 2014-06-05 2016-01-20 武汉格罗宁根医药科技有限公司 N-3-取代磺酰胺乙基-5-环丙烷螺环乙内酰脲衍生物及其制备方法和应用
TWI828952B (zh) 2015-06-05 2024-01-11 美商艾佛艾姆希公司 作為除草劑之嘧啶氧基苯衍生物
GB201521751D0 (en) * 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) * 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
EP3555073A1 (en) 2016-12-16 2019-10-23 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
CA3062135A1 (en) * 2017-05-02 2018-11-08 Fmc Corporation Pyrimidinyloxy benzo-fused compounds as herbicides
WO2018220762A1 (ja) * 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
CN107556262B (zh) * 2017-08-14 2020-05-22 四川大学 一种2-取代基芳并噁唑的制备方法
DE112018007799T5 (de) * 2018-07-03 2021-03-25 Cummins Emission Solutions Inc. Zersetzungsreaktor mit körpermischung
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
KR102854594B1 (ko) * 2018-10-16 2025-09-02 오티포니 세라피틱스 리미티드 신규한 화합물
MY210184A (en) 2018-11-30 2025-08-31 Otsuka Pharma Co Ltd Heterocyclic compounds for the treatment of epilepsy
GB201821066D0 (en) * 2018-12-21 2019-02-06 Univ Oxford Innovation Ltd Sleep modulation
US12139473B2 (en) * 2019-03-25 2024-11-12 Bionomics Limited Substituted-N-heteroaryl compounds and uses thereof
BR112022013339A2 (pt) 2020-02-06 2022-09-13 Autifony Therapeutics Ltd Moduladores de kv3
US11638606B2 (en) 2020-04-15 2023-05-02 Bard Peripheral Vascular, Inc. Bipolar electrosurgical pleura sealing device, system, and method of operating same
EP3901152A1 (en) * 2020-04-23 2021-10-27 F. Hoffmann-La Roche AG Kv3 enhancers for the treatment of cognitive disorders
CN112213428A (zh) * 2020-10-13 2021-01-12 辽宁科技大学 一种超临界co2中进行非催化乙酰基化反应及其在线检测方法
KR20240046748A (ko) * 2021-08-10 2024-04-09 오티포니 세라피틱스 리미티드 칼륨 채널 조절제
KR20230084419A (ko) * 2021-12-03 2023-06-13 (주)인비보텍 난청 또는 이명의 예방 또는 치료용 조성물
WO2024121552A1 (en) 2022-12-06 2024-06-13 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069951A1 (en) * 2009-12-11 2011-06-16 Glaxo Group Limited Imidazolidinedione derivatives

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3474170A (en) * 1964-01-23 1969-10-21 Fmc Corp Pesticidal carbamates of dihydrobenzofuranols
US4143055A (en) * 1978-03-27 1979-03-06 Gruppo Lepetit S.P.A. 2,4,6-trisubstituted-2,3-dihydro-benzofuran derivatives
DE3015090A1 (de) 1980-04-19 1981-10-22 Basf Ag, 6700 Ludwigshafen ]-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one, verfahren zu ihrer herstellung, diese enthaltende fungizide und verfahren zur bekaempfung von pilzen mit diesen verbindungen
DE3133405A1 (de) 1981-08-24 1983-03-10 Basf Ag, 6700 Ludwigshafen 1-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one und diese enthaltende fungizide
US4675403A (en) 1985-10-16 1987-06-23 American Home Products Corporation 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity
JP2514945B2 (ja) * 1987-02-05 1996-07-10 三井石油化学工業株式会社 芳香族アミン誘導体
DE3810848A1 (de) 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
DE3836175A1 (de) 1988-10-24 1990-05-03 Bayer Ag Fluor enthaltende phenole
CA2007830A1 (en) * 1989-01-18 1990-07-18 Shuji Ozawa 2,3-dihydro-3, 3-dimethyl-5-trifluoromethanesulfonyloxy-benzofurans, process for producing them and herbicides containing them
WO1991004027A1 (en) 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
JPH03153606A (ja) * 1989-11-10 1991-07-01 Mitsui Petrochem Ind Ltd 除草剤組成物
US5362878A (en) 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
DK123493D0 (da) 1993-11-01 1993-11-01 Lundbeck & Co As H Compounds
MX9708802A (es) 1995-05-17 1998-02-28 Du Pont Amidas ciclicas fungicidas.
WO1996036229A1 (en) 1995-05-17 1996-11-21 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
KR19990028230A (ko) 1995-06-20 1999-04-15 미리암 디. 메코너헤이 살절지동물성 및 살진균성 시클릭 아미드
BR9711816A (pt) 1996-08-01 1999-08-31 Du Pont Composto, composição fungicida, método para controlar doenças de plantas causadas pelos agentes patogênicos f·ngicos de plantas, composição artropodicida e método para controlar artrópodes.
EP0944314A1 (en) 1996-11-26 1999-09-29 E.I. Du Pont De Nemours And Company Methyl substituted fungicides and arthropodicides
WO1998023155A1 (en) 1996-11-26 1998-06-04 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides
AU6040398A (en) 1997-01-30 1998-08-25 E.I. Du Pont De Nemours And Company Fungicidal compositions
JP4171549B2 (ja) 1998-01-28 2008-10-22 大正製薬株式会社 含フッ素アミノ酸誘導体
JP4194715B2 (ja) 1998-08-31 2008-12-10 大正製薬株式会社 ６−フルオロビシクロ［３．１．０］ヘキサン誘導体
JP2000072731A (ja) 1998-08-31 2000-03-07 Taisho Pharmaceut Co Ltd ４−置換−２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体及び製薬用組成物
WO2001007032A1 (en) 1999-07-23 2001-02-01 Shionogi & Co., Ltd. Th2 differentiation inhibitors
CN1431896A (zh) 2000-04-04 2003-07-23 盐野义制药株式会社 含有高脂溶性药物的油性组合物
WO2001076582A1 (fr) 2000-04-05 2001-10-18 Shionogi & Co., Ltd. Micro-emulsions huile dans eau contenant des composes tricycliques ou des preconcentres de ceux-ci
FR2812633A1 (fr) 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
AU2002354410A1 (en) 2001-12-05 2003-06-17 Japan Tobacco Inc. Triazole compound and medicinal use thereof
ATE403426T1 (de) 2002-02-07 2008-08-15 Univ Missouri Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
FI20030030A0 (fi) * 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä
CA2524221A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted heteroaryls as inhibitors of protein tyrosine phosphatases
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
GB0325175D0 (en) 2003-10-28 2003-12-03 Novartis Ag Organic compounds
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US20060211697A1 (en) 2004-12-08 2006-09-21 Liren Huang 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents
JP4644737B2 (ja) 2005-05-13 2011-03-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジアリールヒダントイン化合物
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
LT2656842T (lt) 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
KR101456722B1 (ko) 2006-03-29 2014-10-31 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
KR20100014811A (ko) 2007-04-20 2010-02-11 데시페라 파마슈티칼스, 엘엘씨. 골수증식성 질환 및 기타 증식성 질환의 치료에 유용한 키나제 억제제
EP2252592A1 (de) 2008-02-07 2010-11-24 Sanofi-Aventis Arylchalcogeno-arylalkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
BRPI0918502A2 (pt) * 2008-09-02 2015-12-01 Sanofi Aventis aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos
EP2379534A1 (en) * 2008-12-22 2011-10-26 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
WO2011073114A1 (en) * 2009-12-14 2011-06-23 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
EA023768B1 (ru) 2010-12-06 2016-07-29 Отифони Терапеутикс Лимитед ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
CN103596943B (zh) 2011-06-07 2016-10-12 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
WO2017075565A1 (en) 2015-10-30 2017-05-04 The Johns Hopkins University Mucus penetrating particles with high molecular weight and dense coatings

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069951A1 (en) * 2009-12-11 2011-06-16 Glaxo Group Limited Imidazolidinedione derivatives

Also Published As

Publication number Publication date
EA201390609A1 (ru) 2014-01-30
US20150336936A1 (en) 2015-11-26
IL226256A0 (en) 2013-07-31
CN103328467A (zh) 2013-09-25
US20200179385A1 (en) 2020-06-11
US20190192516A1 (en) 2019-06-27
EA201490922A1 (ru) 2015-03-31
MX2013006343A (es) 2013-09-13
US20220054490A1 (en) 2022-02-24
US10555945B2 (en) 2020-02-11
US9833452B2 (en) 2017-12-05
US20210023084A1 (en) 2021-01-28
BR112013013914B1 (pt) 2021-10-26
KR20130138815A (ko) 2013-12-19
AU2011340258A1 (en) 2013-05-30
US10835534B2 (en) 2020-11-17
IL253102A0 (en) 2017-08-31
US20140323508A1 (en) 2014-10-30
CA2817205A1 (en) 2012-06-14
US20190000849A1 (en) 2019-01-03
JP5913357B2 (ja) 2016-04-27
EA023768B1 (ru) 2016-07-29
SG11201402529RA (en) 2014-06-27
US20200360379A1 (en) 2020-11-19
US10098881B2 (en) 2018-10-16
EA027532B1 (ru) 2017-08-31
WO2012076877A1 (en) 2012-06-14
JP6118927B2 (ja) 2017-04-19
CA2817205C (en) 2020-04-07
JP2013544873A (ja) 2013-12-19
SG190203A1 (en) 2013-06-28
PL2649066T3 (pl) 2017-04-28
US20160251340A1 (en) 2016-09-01
CN103328467B (zh) 2016-08-10
US20170273981A1 (en) 2017-09-28
IL253104A0 (en) 2017-08-31
US9346790B2 (en) 2016-05-24
EP2649066B1 (en) 2015-10-21
BR112013013914A2 (pt) 2016-09-13
US11583527B2 (en) 2023-02-21
US20160317537A1 (en) 2016-11-03
DK2649066T3 (en) 2016-01-11
IL253102B (en) 2018-04-30
US20130267510A1 (en) 2013-10-10
US10265316B2 (en) 2019-04-23
HK1190395A1 (en) 2014-07-04
AU2011340258B2 (en) 2016-05-19
US11197859B2 (en) 2021-12-14
ZA201403529B (en) 2020-03-25
MX338489B (es) 2016-04-18
JP2016145215A (ja) 2016-08-12
US9133175B2 (en) 2015-09-15
US11541052B2 (en) 2023-01-03
US20180036308A1 (en) 2018-02-08
US9422272B2 (en) 2016-08-23
EP2649066A1 (en) 2013-10-16
KR101862375B1 (ko) 2018-05-29
ES2560304T3 (es) 2016-02-18

Similar Documents

Publication Publication Date Title
AU2011340258C1 (en) Hydantoin derivatives useful as Kv3 inhibitors
AU2012349847B2 (en) Hydantoin derivatives useful as Kv3 inhibitors
AU2010330048B2 (en) Imidazolidinedione derivatives
HK1190395B (en) Hydantoin derivatives useful as kv3 inhibitors
HK1203072B (en) Hydantoin derivatives useful as kv3 inhibitors

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 JUL 2016 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 JUL 2016

FGA Letters patent sealed or granted (standard patent)